Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

    Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent.

    23 May 2017 | HIV i-Base
  • CHMP recommends for approval generic version of Atripla

    At its May meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.

    22 May 2017 | EATG
  • Gilead's last chronic HIV drug — and what it plans to do now

    Gilead Sciences Inc. — whose HIV-fighting drugs have helped to nearly triple the lives of people with the HIV virus and reduce the number of pills patients pop from 25 to one — expects this fall to ask government regulators to approve its final chronic HIV treatment.

    11 May 2017 | San Francisco Business Times
  • Scott Gottlieb wins confirmation as FDA commissioner

    Dr. Scott Gottlieb is headed back to the Food and Drug Administration. By a vote of 57 to 42, the Senate on Tuesday confirmed Gottlieb, a former FDA deputy commissioner, as the agency’s next chief.

    10 May 2017 | STAT
  • Gilead slowly rolls out ads for Truvada for PrEP — 4 years after approval

    Gradually ramping up promotion of its HIV-prevention pill, Gilead Sciences has turned to humor, dating apps, and social-media sites like Tumblr and Snapchat to raise awareness about HIV prevention.

    08 May 2017 | Medical Marketing & Media
  • The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 63 HIV/AIDS Patient Groups

    In 2016, HIV/AIDS patient groups show higher regard for pharma than patient groups from most other therapy areas.

    08 May 2017 | PatientView
  • EMA and heads of national competent authorities discuss consequences of Brexit

    The European Medicines Agency (EMA) organised an information meeting yesterday with members of its Management Board and heads of the National Competent Authorities (NCAs) of the EU/EEA Member States. The goal was to start discussing how the work related to the evaluation and monitoring of medicines will be shared between Member States in view of the United Kingdom’s (UK) withdrawal from the European Union.

    02 May 2017 | EMA
  • The CEO of HIV

    Michael Weinstein’s AIDS Healthcare Foundation treats an enormous number of patients — and makes an enormous amount of money. Is that why so many activists distrust him?

    26 April 2017 | New York Times
  • Open letter to Gilead Sciences about PrEP by EATG and the PrEP in Europe Initiative

    Please read and share this letter signed by the European AIDS Treatment Group and the PrEP in Europe Initiative (PEI), a partnership of European prevention and policy NGOs. It requests Gilead Sciences to surrender their patent of Truvada® or otherwise make it possible for Truvada or generic equivalents of it to be offered at greatly reduced prices to all European health care systems so that it can be used as HIV pre-exposure prophylaxis (PrEP).

    18 April 2017 | EATG / PrEP in Europe
  • Top 10 Pharmaceutical Companies 2017

    The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

    18 April 2017 | LinkedIn
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.